While Goldman Sachs maintains a Buy rating on Vir Biotechnology, the lowering of the price target from $51 to $28 could create some uncertainty among investors. This could potentially lead to short-term volatility in the stock price, but the overall impact is neutral as the Buy rating is still maintained.